|
業務類別
|
Biotechnology |
|
業務概覽
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
| 公司地址
| 1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801 |
| 電話號碼
| +1 484 254-6134 |
| 傳真號碼
| -- |
| 公司網頁
| https://nrxpharma.com |
| 員工數量
| -- |
| Mr. Matthew Duffy |
Chief Business Officer; Co-Chief Executive Officer, Hope Therapeutics, Inc. |
美元 338.00K |
14/03/2025 |
| Mr. Michael S. Abrams |
Chief Financial Officer, Treasurer and Principal Accounting Officer |
美元 20.31K |
23/02/2026 |
| Dr. Riccardo Panicucci, PhD |
Chief Manufacturing and Technology Officer |
-- |
23/02/2026 |
| Dr. Jonathan C. Javitt,M.D.,M.P.H. |
Chairman of the Board, Chief Scientist and Interim Chief Executive Officer |
美元 575.00K |
23/02/2026 |
| Mr. Joseph Michael Casper |
Chief Operating Officer |
-- |
02/02/2026 |
|
|
| Dr. Jonathan C. Javitt,M.D.,M.P.H. |
Chairman of the Board, Chief Scientist and Interim Chief Executive Officer |
23/02/2026 |
| Dr. Dennis McBride, PhD |
Independent Director |
23/02/2026 |
| Mr. Patrick J. Flynn |
Independent Director |
23/02/2026 |
| Mr. Mike Taylor |
Director |
22/01/2025 |
| Mr. Michael Taylor |
Independent Director |
23/02/2026 |
| Mr. Chaim Hurvitz |
Independent Director |
23/02/2026 |
|
|
|
|
